Current Cardiology Reports

, Volume 4, Issue 4, pp 341–347 | Cite as

New biomarkers in the risk stratification of patients with suspected acute myocardial infarction

  • Bret A. Rogers
  • L. Kristin Newby


The acute coronary syndromes (ACS) remain a diagnostic and prognostic challenge for today’s physician. Over the past decade, studies have identified several serologic biomarkers to aid the clinician in assessing risk and predicting outcomes in ACS. Still others are being identified that show promise for increasing the accuracy with which this risk is assessed. However, further research remains necessary to identify the perfect cardiac biomarker or combination of markers and to define their roles in clinical management of ACS patients.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    The Joint European Society of Cardiology/American College of Cardiology Committee: Myocardial infarction redefined—a consensus statement of the joint ECS/ACC committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000, 36:959–969. This reference provides the revised criteria for definition of MI reflecting broad international consensus. The redefinition emphasizes the diagnostic sensitivity and prognostic importance of troponin testing and also provides standards for defining the reference limit and assay precision at the reference limit.CrossRefGoogle Scholar
  2. 2.
    Hamm C, Goldmann BU, Heeschen C, et al.: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997, 337:1648–1653.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohman EM, Armstrong PW, Christenson RH, et al., for the GUSTO IIa Investigators: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996, 335:1333–1341.PubMedCrossRefGoogle Scholar
  4. 4.
    Antman EM, Tanasijevic MJ, Thompson B, et al.: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342–1349.PubMedCrossRefGoogle Scholar
  5. 5.
    Ottani F, Galvani M, Nicolini FA, et al.: Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000, 140:917–927. A thorough and well-done systematic overview and meta-analysis of the results of studies of troponin testing across the spectrum of ACS presentations. Clearly presents the prognostic importance of baseline troponin elevations in both ST-segment elevation and non-ST-segment elevation ACS.PubMedCrossRefGoogle Scholar
  6. 6.
    Heidenreich PA, Alloggiamento T, Melsop K, et al.: The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001, 38:478–485.PubMedCrossRefGoogle Scholar
  7. 7.
    Lindahl B, Venge P, Wallentin L: Troponin T identifies patients with unstable coronary artery disease who benefit from longterm antithrombotic protection. J Am Coll Cardiol. 1997, 29:43–48.PubMedCrossRefGoogle Scholar
  8. 8.
    Hamm CW, Heeschen C, Goldmann B, et al.: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999, 340:1623–1629.PubMedCrossRefGoogle Scholar
  9. 9.
    Heeschen C, van den Brand MJ, Hamm CW, Simoons ML: Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation. 1999, 100:1509–1514.PubMedGoogle Scholar
  10. 10.
    Heeschen C, Hamm CW, Goldmann B, Deu A, et al.: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999, 354:1757–1762.PubMedCrossRefGoogle Scholar
  11. 11.
    Newby LK, Ohman EM, Christenson RH, et al.: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B troponin T substudy. Circulation. 2001, 103:2891–2896.PubMedGoogle Scholar
  12. 12.
    Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189–198. Meta-analysis of all trials of GP IIb/IIIa inhibitors in ACS clearly demonstrating the troponin status by treatment interaction in which patients who are troponin-positive at baseline derive enhanced benefit from treatment with GP IIb/IIIa inhibitors relative to patients who are troponin-negative at baseline.PubMedCrossRefGoogle Scholar
  13. 13.
    Morrow DA, Cannon CP, Rifai N, et al.: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non- ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001, 286:2405–2412.PubMedCrossRefGoogle Scholar
  14. 14.
    Wallentin L, Lagerqvist B, Husted S, et al.: Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet. 2000, 356:9–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Lindahl B, Diderholm E, Lagerqvist B, et al.: Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001, 38:979–986.PubMedCrossRefGoogle Scholar
  16. 16.
    Srinivas VS, Cannon CP, Gibson CM, et al.: Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a TIMI 10B substudy. Am Heart J. 2001, 142:29–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Newby LK, Storrow AB, Gibler WB, et al.: Bedside multimarker testing for risk stratification in chest pain units: the CHECKMATE study. Circulation. 2001, 103:1832–1837. This is the first prospective study to demonstrate the importance of a multimarker strategy of biomarker testing including myoglobin, and performed at the point of care to identify and risk stratify high-risk patients from among those with low-risk presentations with chest pain and nondiagnostic ECGs.PubMedGoogle Scholar
  18. 18.
    Heeschen C, Hamm CW, Bruemmer J, Simoons ML, for the CAPTURE investigators: Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol. 2000, 35:1535–1542.PubMedCrossRefGoogle Scholar
  19. 19.
    Morrow DA, Rifai N, Antman EM, et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998, 31:1460–1465.PubMedCrossRefGoogle Scholar
  20. 20.
    Lindahl B, Toss H, Siegbahn A, et al.: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000, 343:1139–1147.PubMedCrossRefGoogle Scholar
  21. 21.
    Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease. JAMA. 2001, 286:2107–2113. This study demonstrates that a marker of inflammation, interleukin- 6, may be useful in discriminating acute coronary syndrome patients who could benefit preferentially from an early invasive strategy of management.PubMedCrossRefGoogle Scholar
  22. 22.
    De Lemos JA, Marrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014–1021. This study demonstrates the possibility of using non-necrosis markers, in this case BNP, to augment clinical, ECG and troponins tools in risk stratification of patients across the spectrum of ACS.PubMedCrossRefGoogle Scholar
  23. 23.
    Bayes-Genis A, Conover CA, Overgaard MT, et al.: Pregnancyassociated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001, 345:1022–1029.PubMedCrossRefGoogle Scholar
  24. 24.
    Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med. 2000, 19:311–315.PubMedCrossRefGoogle Scholar
  25. 25.
    Bar-Or D, Winkler JV, Vanbenthuysen K, et al.: Reduced albumin- cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J. 2001, 141:985–991.PubMedCrossRefGoogle Scholar
  26. 26.
    Okamoto F, Sohmiya K, Ohkaru Y, et al.: Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med. 2000, 38:231–238.PubMedCrossRefGoogle Scholar
  27. 27.
    De Groot MJ, Muijtjens AM, Simoons ML, et al.: Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma. Heart. 2001, 85:278–285.PubMedCrossRefGoogle Scholar
  28. 28.
    Watanbe T, Ohkubo Y, Matsuoka H: Development of a simple whole blood panel test for detection of human heart-type fatty acid-binding protein. Clin Biochem. 2001, 34:257–263.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Bret A. Rogers
    • 1
  • L. Kristin Newby
    • 1
  1. 1.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations